Press material from the press conference held on February 21st 2019.
Advantages of modern blood-based cancer diagnostics
Patient-friendly method for diagnosis of breast cancer
Advanced diagnostics for risk groups
Possibility of therapy monitoring
Possibility of identifying response to therapy or resistance to therapy
Options for aftercare
Simple blood test for laboratories
Only small amounts of blood needed for detection of breast cancer
Diagnosis of cancer on the basis of biomarkers
Basis for assessment of cancer risk
Adds to range of optical diagnostic procedures such as mammography, ultrasonography and MRI
Explanation of the procedure
Breast cancer is the most common form of cancer affecting women in Germany. In 2018, some 70,000 women developed breast cancer, accounting for about 30 percent of all new cancer cases. With early detection, however, the chance of a full recovery is very high at 95 percent.
The University Women's Hospital at Heidelberg University Hospital has developed a new method that enables the detection of breast cancer. The test thus complements the diagnostic spectrum of optical diagnostic procedures such as mammography, ultrasound or MRT. Now this test is to be transferred by HeiScreen into clinical application. The market launch of the test for the detection of breast cancer is planned for later this year.
"The blood test developed by our team of researchers offers a new and revolutionary opportunity to detect breast cancer quickly and non-invasively using biomarkers in the blood."
- Professor Christof Sohn, Managing Medical Director of the University Women's Hospital in Heidelberg
The blood test is based on the liquid biopsy principle. This involves obtaining information about a disease using bodily fluids such as blood, urine or sputum by examining messenger substances from tumour cells in a liquid sample. In the blood of women suffering from breast cancer, 15 different biomarkers were identified that can be used to detect even small tumours.
Only a few millilitres of blood are needed for the test, which any laboratory should be able to perform. The new blood-based procedure is significantly less of a burden on women because it is neither painful nor associated with radiation exposure.
The test can be performed on women of all ages. The latest study results show an overall sensitivity of 75 percent. Sensitivity indicates the percentage of patients actually detected by the test. Age-dependent differences were discovered: sensitivity of 86 percent for the under-50s and 60 percent for the over-50s. Younger women under 50 years of age and women with a high familial risk of breast cancer, for whom a mammogram would be of limited value because of dense mammary gland tissue, for example, or for whom traditional imaging methods are contraindicated due to other risk factors, benefit in particular. Here a sensitivity of 80 to 90 percent was achieved.
The goal of the ongoing study is to further specify and improve the significance, sensitivity and usability of the procedure through future analyses. Its usability for other forms of cancer, e.g. ovarian cancer, is also being investigated. Current interim results show a sensitivity of up to 80 percent.
Innovation from Heidelberg
The scientific research into the blood test for breast cancer was carried out at the University Women's Hospital, a department of Heidelberg University Hospital. The University Hospital Heidelberg is one of the largest medical centres in Germany; the Medical Faculty of the University of Heidelberg is among the most internationally renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new diagnostic methods and therapies and implementing them rapidly for patients.
Please use this contact form for further information or if you would like to send a request to HeiScreen.